首页> Cancer> Primary results and characterization of patients with exceptional outcomes in a phase 1b study combining PARP and MEK inhibition, with or without anti-PD-L1, for BRCA wild-type, platinum-sensitive, recurrent ovarian cancer.

Primary results and characterization of patients with exceptional outcomes in a phase 1b study combining PARP and MEK inhibition, with or without anti-PD-L1, for BRCA wild-type, platinum-sensitive, recurrent ovarian cancer.

导出原文传递

翻译打印收藏纠错

第一作者： David,Mutch

第一单位： Division of Gynecology Oncology, Washington University School of Medicine, St Louis, Missouri, USA.

作者： David,Mutch ^[1] ; Athina,Voulgari ^[2] ; Xian Marissa,Chen ^[3] ; William H,Bradley ^[4] ; Ana,Oaknin ^[5] ; José Alejandro,Perez Fidalgo ^[6] ; Fernando Galvez,Montosa ^[7] ; Antonio Casado,Herraez ^[8] ; Robert W,Holloway ^[9] ; Matthew A,Powell ^[1] ; Malgorzata,Nowicka ^[3] ; Gabriele,Schaefer ^[10] ; Mark,Merchant ^[11] ; Yibing,Yan ^[3]

作者单位： Division of Gynecology Oncology, Washington University School of Medicine, St Louis, Missouri, USA. ^[1] Global Product Development Clinical Science, Roche Products Ltd., Welwyn Garden City, UK. ^[2] Translational Medicine, Genentech, Inc., South San Francisco, California, USA. ^[3] Department of Obstetrics and Gynecology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA. ^[4] Medical Oncology Service, Vall d'Hebron Institute of Oncology, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain. ^[5] Hospital Clínico Universitario Valencia, Biomedical Research Institute INCLIVA, Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Valencia, Spain. ^[6] Medical Oncology Department, Hospital Universitario de Jaén, Jaén, Spain. ^[7] Department of Medical Oncology, Hospital Universitario San Carlos, Universidad Complutense, IdISSC, Madrid, Spain. ^[8] Gynecologic Oncology, AdventHealth Cancer Institute, Orlando, Florida, USA. ^[9] Molecular Oncology, Genentech, Inc., South San Francisco, California, USA. ^[10] Translational Oncology, Genentech, Inc., South San Francisco, California, USA. ^[11]

关键词 MEK inhibitor MKNK1 NF1 PARP inhibitor immune checkpoint blockade ovarian cancer